Abstract: An image processing device includes a reception unit and a setting unit. The reception unit receives an input image signal, and a synchronization signal used to generate an output image signal on a basis of the input image signal. The setting unit sets, after the reception unit receives the synchronization signal, a reception prohibition period that prohibits reception of a different synchronization signal by the reception unit.

Abstract: An image processing device includes a reception unit that receives an input image signal, and a synchronization signal used to generate an output image signal on a basis of the input image signal. In a case in which, after receiving the synchronization signal, the reception unit does not receive a next synchronization signal within a predetermined reception period, the reception unit conducts an automatic reception process that treats the next synchronization signal as being received.

Abstract: An image processing device includes a reception unit and a generation unit. The reception unit receives an input image signal, and a synchronization signal used to generate an output image signal on a basis of the input image signal. The generation unit generates, in a case in which the reception unit receives an initial synchronization signal of a unit of image reading, a synchronization signal for a subsequent input image signal. The reception unit receives the synchronization signal generated by the generation unit.

Abstract: An image processing device includes a reception unit and a recognition unit. The reception unit receives an input image signal and a synchronization signal including a signal pattern. In a case in which the signal pattern corresponds to a predetermined prescribed pattern, the recognition unit recognizes the synchronization signal as a genuine synchronization signal to be used to generate an output image signal on a basis of the input image signal.

Abstract: An image processing device includes a reception unit and a generation unit. The reception unit receives an input image signal, and a synchronization signal used to generate an output image signal on a basis of the input image signal. The generation unit generates, in a case in which the reception unit receives an initial synchronization signal of a unit of image reading, a synchronization signal for a subsequent input image signal. The reception unit receives the synchronization signal generated by the generation unit.

Abstract: An image processing device includes a reception unit and a setting unit. The reception unit receives an input image signal, and a synchronization signal used to generate an output image signal on a basis of the input image signal. The setting unit sets, after the reception unit receives the synchronization signal, a reception prohibition period that prohibits reception of a different synchronization signal by the reception unit.

Abstract: An image processing device includes a reception unit that receives an input image signal, and a synchronization signal used to generate an output image signal on a basis of the input image signal. In a case in which, after receiving the synchronization signal, the reception unit does not receive a next synchronization signal within a predetermined reception period, the reception unit conducts an automatic reception process that treats the next synchronization signal as being received.

Abstract: An image processing device includes a reception unit and a recognition unit. The reception unit receives an input image signal and a synchronization signal including a signal pattern. In a case in which the signal pattern corresponds to a predetermined prescribed pattern, the recognition unit recognizes the synchronization signal as a genuine synchronization signal to be used to generate an output image signal on a basis of the input image signal.

Abstract: A compound which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy is provided.

Abstract: [Problem] A compound which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy is provided. [Means for Solution] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic action, and have found that an amide compound or a salt thereof exhibits an EP4 receptor antagonistic action, thereby completing the present invention. The amide compound or a salt thereof has an EP4 receptor antagonistic action, and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating various EP4-related diseases, for example, chronic renal failure and/or diabetic nephropathy.

Abstract: An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.

Abstract: [Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.

Abstract: Provided is an image reading apparatus including a reading member that reads a document on which an image is recorded, a calibration process section that performs a shading process to correct unevenness in brightness based on a result acquired in such a way that the reading member reads a preset color, and a heating control section that heats the reading member during a preset period when power is supplied from a state in which power is not supplied.

Abstract: Provided is an image reading apparatus including a reading member that reads a document on which an image is recorded, a calibration process section that performs a shading process to correct unevenness in brightness based on a result acquired in such a way that the reading member reads a preset color, and a heating control section that heats the reading member during a preset period when power is supplied from a state in which power is not supplied.

Abstract: [Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.

Abstract: [Problem] An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. [Means for Solution] It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.

Abstract: [Problems] A compound, which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy, is provided. [Solving Means] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic activity, and confirmed that the amide compound of the present invention has an EP4 receptor antagonistic activity, thereby completing the present invention. The amide compound of the present invention has an EP4 receptor antagonistic activity, and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating various EP4-related diseases, for example, chronic renal failure and/or diabetic nephropathy, and the like.

Abstract: [Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine. [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.

Abstract: Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.

Abstract: [Problems] A compound, which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy, is provided. [Solving Means] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic activity, and confirmed that the amide compound of the present invention has an EP4 receptor antagonistic activity, thereby completing the present invention. The amide compound of the present invention has an EP4 receptor antagonistic activity, and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating various EP4-related diseases, for example, chronic renal failure and/or diabetic nephropathy, and the like.